3.20
price up icon0.95%   0.03
after-market Dopo l'orario di chiusura: 3.22 0.02 +0.63%
loading
Precedente Chiudi:
$3.17
Aprire:
$3.17
Volume 24 ore:
1.16M
Relative Volume:
0.72
Capitalizzazione di mercato:
$227.72M
Reddito:
-
Utile/perdita netta:
$-192.96M
Rapporto P/E:
-0.9697
EPS:
-3.3
Flusso di cassa netto:
$-167.04M
1 W Prestazione:
-2.14%
1M Prestazione:
+32.78%
6M Prestazione:
+42.22%
1 anno Prestazione:
+12.68%
Intervallo 1D:
Value
$3.15
$3.2999
Intervallo di 1 settimana:
Value
$2.881
$3.3499
Portata 52W:
Value
$0.783
$3.39

Ventyx Biosciences Inc Stock (VTYX) Company Profile

Name
Nome
Ventyx Biosciences Inc
Name
Telefono
(858) 945-2393
Name
Indirizzo
12790 EL CAMINO REAL, SUITE 200, SAN DIEGO
Name
Dipendente
79
Name
Cinguettio
Name
Prossima data di guadagno
2024-11-04
Name
Ultimi documenti SEC
Name
VTYX's Discussions on Twitter

Confronta VTYX con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
VTYX
Ventyx Biosciences Inc
3.20 225.58M 0 -192.96M -167.04M -3.30
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
472.27 120.73B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
564.64 61.80B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
328.00 42.46B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
591.74 35.22B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
296.46 31.99B 3.81B -644.79M -669.77M -6.24

Ventyx Biosciences Inc Stock (VTYX) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2024-03-12 Aggiornamento Oppenheimer Perform → Outperform
2024-03-12 Aggiornamento Wells Fargo Equal Weight → Overweight
2023-11-07 Downgrade H.C. Wainwright Buy → Neutral
2023-11-07 Downgrade Morgan Stanley Overweight → Equal-Weight
2023-11-07 Downgrade Oppenheimer Outperform → Perform
2023-11-07 Downgrade Stifel Buy → Hold
2023-11-07 Downgrade Wells Fargo Overweight → Equal Weight
2023-06-14 Ripresa Credit Suisse Outperform
2023-03-21 Iniziato Wells Fargo Overweight
2022-12-19 Iniziato Goldman Buy
2022-11-17 Iniziato Morgan Stanley Overweight
2022-09-07 Iniziato Stifel Buy
2022-09-01 Iniziato H.C. Wainwright Buy
2022-05-09 Iniziato Credit Suisse Outperform
2022-03-31 Iniziato Canaccord Genuity Buy
2022-02-01 Iniziato Oppenheimer Outperform
2021-11-15 Iniziato Jefferies Buy
2021-11-15 Iniziato Piper Sandler Overweight
Mostra tutto

Ventyx Biosciences Inc Borsa (VTYX) Ultime notizie

pulisher
Jul 24, 2025

Is Ventyx Biosciences Inc. a good long term investmentUnrivaled growth potential - Autocar Professional

Jul 24, 2025
pulisher
Jul 23, 2025

Ventyx Biosciences Inc. Stock Analysis and ForecastSuperior risk-adjusted returns - Autocar Professional

Jul 23, 2025
pulisher
Jul 22, 2025

What analysts say about Ventyx Biosciences Inc. stockRecord-setting profit potential - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

Why Ventyx Biosciences Inc. stock attracts strong analyst attentionSmart Return Focused Trading - Newser

Jul 22, 2025
pulisher
Jul 21, 2025

Is Ventyx Biosciences (NASDAQ:VTYX) In A Good Position To Invest In Growth? - Yahoo Finance

Jul 21, 2025
pulisher
Jul 20, 2025

What drives Ventyx Biosciences Inc. stock priceFree Stock Market Real-Time Monitoring - jammulinksnews.com

Jul 20, 2025
pulisher
Jul 16, 2025

What makes Ventyx Biosciences Inc. stock price move sharplyFree Insider Trading Tips - Newser

Jul 16, 2025
pulisher
Jul 15, 2025

How Ventyx Biosciences Inc. stock performs during market volatilityAlpha Stock Ideas - Newser

Jul 15, 2025
pulisher
Jul 12, 2025

Wealth Enhancement Advisory Services LLC Invests $28,000 in Ventyx Biosciences, Inc. (NASDAQ:VTYX) - Defense World

Jul 12, 2025
pulisher
Jul 10, 2025

Ventyx Biosciences (VTYX) Upgraded to Strong Buy: What Does It Mean for the Stock? - Yahoo Finance

Jul 10, 2025
pulisher
Jul 10, 2025

Analyzing the Impact of Earnings Reports on Ventyx Biosciences Inc Inc. (VTYX) Price Performance - investchronicle.com

Jul 10, 2025
pulisher
Jul 03, 2025

Class Action Filed Against Ventyx Biosciences, Inc. (VTYX)April 30, 2024 Deadline to JoinContact Levi & Korsinsky - ACCESS Newswire

Jul 03, 2025
pulisher
Jul 03, 2025

Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Ventyx Biosciences, Inc. (VTYX) Shareholders - ACCESS Newswire

Jul 03, 2025
pulisher
Jun 30, 2025

Ventyx Biosciences, Inc.(NasdaqGS: VTYX) dropped from Russell 3000E Index - MarketScreener

Jun 30, 2025
pulisher
Jun 30, 2025

Ventyx Biosciences, Inc.(NasdaqGS: VTYX) dropped from Russell 3000 Value Index - MarketScreener

Jun 30, 2025
pulisher
Jun 27, 2025

Ventyx Biosciences, Inc. (NASDAQ:VTYX) Shares Sold by Rhumbline Advisers - Defense World

Jun 27, 2025
pulisher
Jun 23, 2025

Canaccord maintains buy rating on Ventyx stock after positive trial results - Investing.com

Jun 23, 2025
pulisher
Jun 18, 2025

Ventyx stock steady as Parkinson’s drug shows biomarker reductions By Investing.com - Investing.com India

Jun 18, 2025
pulisher
Jun 18, 2025

Ventyx reports positive outcomes from trial of VTX3232 for Parkinson’s - Yahoo Finance

Jun 18, 2025
pulisher
Jun 18, 2025

Ventyx Therapeutics' VTX3232: A Neuroinflammation Breakthrough with Orphan Drug Pricing Power - AInvest

Jun 18, 2025
pulisher
Jun 17, 2025

Ventyx Biosciences Inc’s Mixed Bag: Down -9.22% in 6 Months, Down 58.21% in 30 Days - investchronicle.com

Jun 17, 2025
pulisher
Jun 17, 2025

Ventyx Biosciences Holds Steady Despite Encouraging Early Parkinson’s Trial Results - MSN

Jun 17, 2025
pulisher
Jun 17, 2025

Ventyx Biosciences Announces Positive Top-Line Data from - GlobeNewswire

Jun 17, 2025
pulisher
Jun 17, 2025

Ventyx Biosciences Shares Fall After Tier 2 Exploratory Biomarkers Remain Stable in Parkinson's Study - MarketScreener

Jun 17, 2025
pulisher
Jun 17, 2025

Ventyx reports positive Phase 2a results for Parkinson’s drug - Investing.com

Jun 17, 2025
pulisher
Jun 17, 2025

Ventyx Biosciences Insiders Placed Bullish Bets Worth US$1.26m - Yahoo.co

Jun 17, 2025
pulisher
Jun 17, 2025

Ventyx Biosciences' Study of VTX3232 Met Safety, Tolerability Objectives - MarketWatch

Jun 17, 2025
pulisher
Jun 17, 2025

Ventyx posts mid-stage trial win for Parkinson’s drug (VTYX) - Seeking Alpha

Jun 17, 2025
pulisher
Jun 17, 2025

Ventyx Biosciences stock trades flat despite positive parkinson’s drug trial data - Investing.com Canada

Jun 17, 2025
pulisher
Jun 17, 2025

Ventyx Biosciences Announces Positive Data From Its Phase 2A Trial Evaluating Vtx3232 In Patients With Early-Stage Parkinson'S Disease - marketscreener.com

Jun 17, 2025
pulisher
Jun 17, 2025

Ventyx Biosciences Announces Positive Data From Its Phase 2A Trial Evaluating Vtx3232 In Patients With Early-Stage Parkinson’S Disease - TradingView

Jun 17, 2025
pulisher
Jun 17, 2025

Ventyx reports positive Phase 2a results for Parkinson’s drug By Investing.com - Investing.com India

Jun 17, 2025
pulisher
Jun 17, 2025

VTYX Trading Halted as Market Awaits News Update | VTYX Stock News - GuruFocus

Jun 17, 2025

Ventyx Biosciences Inc Azioni (VTYX) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$23.63
price up icon 3.32%
$36.59
price up icon 1.61%
$103.52
price up icon 0.08%
$27.57
price down icon 1.57%
$114.57
price down icon 0.03%
biotechnology ONC
$296.46
price up icon 0.55%
Capitalizzazione:     |  Volume (24 ore):